Antimicrobial Introduction: Coartem, Cidofovir, Maraviroc, Foscarnet, Griseofulvin, Natamycin, Anidulafungin, Artesunate, Nifurtimox

Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Pages: 213. Not illustrated. Chapters: Coartem, Cidofovir, Maraviroc, Foscarnet, Griseofulvin, Natamycin, Anidulafungin, Artesunate, Nifurtimox, Halofantrine, Dihydroartemisinin, Fomivirsen, Clotrimazole, Sertaconazole, Penciclovir, Tafenoquine, Melarsoprol, Proguanil, Integrase Inhibitor, Amoscanate, Tipranavir, Tolnaftate, Butenafine, Haloprogin, Nucleoside Analogue, Brivudine, Arsthinol, Buparvaquone, Indinavir, Calamine, Tribendimidine, Fosamprenavir, Trifluridine, Abafungin, Benznidazole, Brilliant Green, Trimetrexate, Polyene Antimycotic, Idoxuridine, Tenofovir/emtricitabine, Amodiaquine, Econazole, Artenimol, Carbadox, Loviride, Tromantadine, Argyrol, Neuraminidase Inhibitor, Artemether, Ornidazole, Antiparasitic, Acrisorcin, Biclotymol, Trizivir, Acedapsone, Artemotil, Climbazole, 8-Aminoquinoline, Dimetridazole, Fosfluconazole, Betadine, Abunidazole, Acediasulfone, Ritiometan, Oxiconazole, Chlorproguanil Hydrochloride-Dapsone-Artesunate, Hamycin, Lucimycin, Ethyl Green, Terconazole, Mitaban, Sulconazole, Macrofilaricide, Antiprotozoal Agent, Lapdap, Cotrifazid, Mebucain, Amylmetacresol, Vosol, Undecoylium Chloride Iodine. Excerpt: Coartem (artemether 20 mg/lumefantrine 120 mg) is an artemisinin-based combination therapy (ACT) indicated for the treatment of acute uncomplicated plasmodium falciparum malaria, the most dangerous form of the disease. Coartem is produced by the Swiss pharmaceutical company, Novartis. Coartem has two key ingredients; artemether, which is a derivative of artemisinin, and lumefantrine (or benflumetol) an antimalarial drug. The combination of these two ingredients has led to one of the most successful malaria treatments of its kind. Coartem is a highly effective and well-tolerated malaria treatment, providing cure rates of up to 97%, even in areas of multi-drug resistance. In 2001, Coartem became the fir...